Stockreport

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

argenx SE - American Depositary Shares  (ARGX) 
PDF       -          Subcutaneous formulation offers potential for increased patient convenience and acceptance -   June 14, 2018 Breda, the Netherlands/Ghent, Bel [Read more]